HCW Biologics Competitors and Similar CompaniesClear all
HCW Biologics's competitors and similar companies include CureVac, Puma Biotechnology, HUYA Bioscience International and AIM ImmunoTech.
 HCW Biologics HCW Biologics is a company developing proprietary immunotherapy candidates to address chronic inflammation through inflammasome modulation and senescent cell reduction. |  Puma Biotechnology Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer. |  HUYA Bioscience International HUYA Bioscience International is a company specializing in the biopharmaceutical products. |  AIM ImmunoTech AIM ImmunoTech (formerly known as Hemispherx Biopharma) is an immuno-tech company focused on the research and development of immunological agents to treat multiple types of cancers and immune-deficiency diseases. | ||
Founding Date | Founding Date 2018 | Founding Date 2000 | Founding Date 2010 | Founding Date 2004 | Founding Date 1990 |
Type | Type Public | Type Public | Type Public | Type Private | Type Public |
Tags | |||||
Locations | Locations Miramar, US HQ | Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US | Locations Los Angeles, US HQ | Locations San Diego, US HQ Chengdu Shi, CN Guangzhou Shi, CN Hangzhou, CN Shenzhen Shi, CN Shenzhen Shi, CN Suzhou Shi, CN see more | Locations Ocala, US HQ New Brunswick, US |
Employees | Employees 40 | Employees 82517% decrease | Employees 27214% decrease | Employees 1113% increase | Employees 3124% increase |
Valuation ($) | Valuation ($) 16.7 m | Valuation ($) 648.3 m | Valuation ($) 136.8 m | Valuation ($) N/A | Valuation ($) 17.1 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $54.2k (FY, 2025) | Revenue (est.) €535.2m (FY, 2024) | Revenue (est.) $228.4m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $88k (FY, 2025) |
Cost of goods | Cost of goods $43.4k (FY, 2025) | Cost of goods €9.7m (FY, 2024) | Cost of goods $58.2m (FY, 2025) | Cost of goods N/A | Cost of goods $128k (FY, 2025) |
Gross profit | Gross profit $10.8k (FY, 2025) | Gross profit €534.4m (FY, 2024) | Gross profit $170.2m (FY, 2025) | Gross profit N/A | Gross profit ($40k) (FY, 2025) |
Net income | Net income ($8m) (FY, 2025) | Net income €162.2m (FY, 2024) | Net income N/A | Net income N/A | Net income ($14m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 24.3m | Total funding raised $ 1.1b | Total funding raised $ 172m | Total funding raised $ 12.6m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
CureVac
HQ
Tübingen, DE
Employees
825↓ 17% decrease
CureVac is a biotechnology company offering messenger RNA (mRNA) technology.
View companyPuma Biotechnology
HQ
Los Angeles, US
Employees
272↓ 14% decrease
Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.
View companyHUYA Bioscience International
HQ
San Diego, US
Employees
111↑ 3% increase
HUYA Bioscience International is a company specializing in the biopharmaceutical products.
View companyAIM ImmunoTech
HQ
Ocala, US
Employees
31↑ 24% increase
AIM ImmunoTech (formerly known as Hemispherx Biopharma) is an immuno-tech company focused on the research and development of immunological agents to treat multiple types of cancers and immune-deficiency diseases.
View company